Jasper Therapeutics (NASDAQ:JSPR) Shares Down 2.7% – Time to Sell?

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s stock price traded down 2.7% on Monday. The company traded as low as $0.5446 and last traded at $0.5550. 335,799 shares changed hands during trading, a decline of 11% from the average daily volume of 375,968 shares. The stock had previously closed at $0.5702.

Wall Street Analyst Weigh In

JSPR has been the subject of several recent analyst reports. William Blair began coverage on shares of Jasper Therapeutics in a report on Wednesday. They issued an “outperform” rating for the company. Wall Street Zen lowered shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Finally, Piper Sandler began coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.33.

Jasper Therapeutics Price Performance

The business’s 50 day moving average price is $0.67 and its 200 day moving average price is $0.70. The stock has a market capitalization of $16.67 million, a P/E ratio of -0.32 and a beta of 3.16.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, analysts forecast that Jasper Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.